-
1 Comment
WuXi AppTec Co., Ltd is currently in a long term uptrend where the price is trading 32.6% above its 200 day moving average.
From a valuation standpoint, the stock is 82.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.7.
WuXi AppTec Co., Ltd's total revenue rose by 31.4% to $5B since the same quarter in the previous year.
Its net income has increased by 562.0% to $592M since the same quarter in the previous year.
Finally, its free cash flow grew by 131.7% to $441M since the same quarter in the previous year.
Based on the above factors, WuXi AppTec Co., Ltd gets an overall score of 5/5.
Exchange | HK |
---|---|
CurrencyCode | HKD |
ISIN | CNE100003F19 |
Sector | Healthcare |
Industry | Diagnostics & Research |
Target Price | 85.8995 |
---|---|
Market Cap | 283B |
PE Ratio | 23.34 |
Dividend Yield | 1.0% |
Beta | 0.76 |
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 2359.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025